 | |
- close
- close
|
Business Wire
Nov 30
Comment
Depomed, Inc. (Nasdaq:DEPO) today announced that it has filed a lawsuit in the United States District Court for the Northern District of California against Lupin Limited and its wholly-owned subsidiary, Lupin Pharmaceuticals, Inc., for infringement
Business Wire
Nov 24
Comment
Depomed, Inc. (NASDAQ:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at Piper Jaffray’s 21st Annual Health Care Conference in New York City, NY on December 1, 2009 at 4:00 pm EST. The company
Business Wire
Nov 18
Comment
Depomed, Inc. (NASDAQ:DEPO) announced today that William Callahan has been promoted to vice president, Operations. Mr. Callahan joined Depomed in 2002 and most recently held the position of senior director, Operations. Mr. Callahan has spent most of
Business Wire
Nov 10
Comment
Depomed, Inc. (NASDAQ:DEPO) today announced that it has received a Paragraph IV certification notice from Lupin Limited advising Depomed of the filing of an Abbreviated New Drug Application (ANDA) with the FDA for a generic version of GLUMETZA®
Business Wire
Nov 3
Comment
Depomed, Inc. (NASDAQ:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at Merriman Curhan Ford’s 6th annual Investor Summit in New York, NY on November 10, 2009 at 1:00 pm EST. The company will
StreetInsider.com
Oct 29
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Depomed+%28DEPO%29+Tops+Q3+EPS+by+11c+on+Strong+Revenues/5056186.html for the full story.
Business Wire
Oct 29
Comment
Depomed, Inc. (NASDAQ: DEPO) today reported financial results for the third quarter ended September 30, 2009. Revenue for the three months ended September 30, 2009 was $23.0 million compared to $14.1 million for the three months ended September 30,
Business Wire
Oct 22
Comment
Depomed, Inc. (NASDAQ:DEPO) announced today that it will release third quarter 2009 financial results after the market closes Thursday, October 29, 2009. The company will host a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its
Business Wire
Oct 22
Comment
Depomed, Inc. (NASDAQ:DEPO) announced today that it has delivered the first formulation under its worldwide license agreement with Covidien focusing on the exclusive development of four products utilizing Depomed’s Acuform® gastric retentive drug
newratings.com
Oct 21
Comment
NEW YORK, October 21 (newratings.com) - Analysts at Caris & Company initiate coverage of DepoMed (ticker: DEPO) with a "buy" rating. The target price is set to $9. [more]
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
DEPO AT A GLANCE
References
| ||||||
|
|
